Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating reissued by stock analysts at HC Wainwright in a report released on Tuesday.

VRX has been the topic of several other reports. Cantor Fitzgerald set a $23.00 price target on shares of Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a “sell” rating and set a $12.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Friday, November 10th. Vetr raised shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “strong-buy” rating and set a $19.72 price target on the stock in a research report on Tuesday, December 5th. TD Securities raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Tuesday, November 7th. Finally, ValuEngine raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research report on Tuesday, December 12th. Six research analysts have rated the stock with a sell rating, ten have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals Intl has a consensus rating of “Hold” and a consensus target price of $18.20.

Shares of Valeant Pharmaceuticals Intl (VRX) opened at $23.84 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84. Valeant Pharmaceuticals Intl has a 1 year low of $8.31 and a 1 year high of $24.43. The stock has a market cap of $8,310.43, a price-to-earnings ratio of 6.11, a price-to-earnings-growth ratio of 0.73 and a beta of -0.22.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $1.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.90 by $0.14. Valeant Pharmaceuticals Intl had a net margin of 15.35% and a return on equity of 51.56%. equities analysts anticipate that Valeant Pharmaceuticals Intl will post 3.82 EPS for the current fiscal year.

In related news, Director John Paulson acquired 344,216 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were bought at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the transaction, the director now directly owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 5.87% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Hexavest Inc. grew its stake in shares of Valeant Pharmaceuticals Intl by 57.9% in the fourth quarter. Hexavest Inc. now owns 545,703 shares of the specialty pharmaceutical company’s stock valued at $11,411,000 after acquiring an additional 199,997 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Valeant Pharmaceuticals Intl by 122.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 32,500 shares of the specialty pharmaceutical company’s stock valued at $675,000 after acquiring an additional 17,900 shares in the last quarter. Montrusco Bolton Investments Inc. acquired a new position in shares of Valeant Pharmaceuticals Intl in the fourth quarter valued at about $6,142,000. Parametric Portfolio Associates LLC grew its stake in shares of Valeant Pharmaceuticals Intl by 21.5% in the third quarter. Parametric Portfolio Associates LLC now owns 980,919 shares of the specialty pharmaceutical company’s stock valued at $14,057,000 after acquiring an additional 173,600 shares in the last quarter. Finally, Moors & Cabot Inc. grew its stake in shares of Valeant Pharmaceuticals Intl by 55.0% in the third quarter. Moors & Cabot Inc. now owns 23,675 shares of the specialty pharmaceutical company’s stock valued at $337,000 after acquiring an additional 8,400 shares in the last quarter. Institutional investors and hedge funds own 49.45% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/16/valeant-pharmaceuticals-intl-vrx-given-hold-rating-at-hc-wainwright.html.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.